Semax

Origin & Classification

Semax is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH fragment 4-10 with the addition of a C-terminal Pro-Gly-Pro sequence, which enhances its stability and biological activity. It is synthesized via solid-phase peptide synthesis and belongs to the class of neuropeptide analogs that mimic fragments of endogenous hormones.

Mechanism & Research Context

Research on Semax investigates its influence on neurotrophic factors and neurotransmitter systems. Studies indicate that Semax may upregulate expression of brain-derived neurotrophic factor (BDNF) and affect signaling pathways involving TrkB receptors. It is also examined for modulation of monoamine levels through interactions with the melanocortin and adenosine receptors. Researchers explore its effects on synaptic plasticity, cognitive processes, and stress resilience, focusing on molecular pathways such as MAPK/ERK, PI3K/AKT, and oxidative stress responses. Semax is utilized as a tool to understand the interplay between peptide signaling, neuroprotection, and cognitive enhancement in preclinical models, avoiding claims of therapeutic efficacy.

Composition & Quality

Semax is supplied as a lyophilized peptide with purity typically above 95 %. Production follows GMP-aligned protocols with purification by HPLC and identification by mass spectrometry. Quality control includes assays for peptide content, sequence verification, and checks for endotoxins and microbial contamination. The peptide is stable under desiccated conditions at low temperature; reconstitution in sterile aqueous buffers is recommended for research use. Certificates of analysis accompany each batch with details on analytical results and storage conditions.

Summary & Unified Disclaimer

This description summarizes the scientific context of the molecule. It is provided for educational and research discussion purposes only. It is not intended to diagnose, treat, cure, or prevent any disease, and no medical or consumption claims are made.